Aventis: enoxaparin studies ultimately disappointing.

Results from the SYNERGY and A to Z trials have shown Aventis SA's Lovenox (enoxaparin) fails to offer significant clinical benefit over unfractionated heparin (UFH) in acute coronary syndrome patients. Physicians will have to consider whether the convenient delivery of enoxaparin will be enough to justify its continued usage over UFH, given the significant cost difference. Aventis will also be concerned that, as well as failing to show superiority in meeting primary endpoints, enoxaparin also showed a slightly higher incidence of bleeding complications against UFH. The A to Z trial randomized approximately 4,000 patients to enoxaparin or UFH on a background of tirofiban and aspirin